IPO Review and Registration Progress - Five companies passed the IPO review last week, including ZhiXin Co. and Shaanxi Tourism, marking the first cultural tourism IPO approval in A-shares in five years [2][3] - Shaanxi Tourism's IPO aims to raise 1.555 billion yuan for projects like cableway upgrades and performance expansion, with its main revenue sources being tourism performances and cableway operations [2] - ZhiXin Co. focuses on automotive stamping parts and related molds, with the review committee expressing concerns about market competition and revenue sustainability [3] New IPO Applications and Terminations - Two IPO applications were accepted last week, including JiaDeLi and Core Medical, with JiaDeLi aiming to raise 725 million yuan for a new production base [9][10] - Two IPO applications were terminated, including HaiChuang Optoelectronics and JianNeng Technology, due to voluntary withdrawal and status change respectively [12] New Stock Listings and Subscription Dynamics - Five new stocks were listed last week, with DanNa Bio experiencing a significant increase of nearly 500% on its first trading day [13] - This week, two new stocks are scheduled for subscription, including NanTe Technology and HaiAn Group, with NanTe aiming for a price of 8.66 yuan per share [15]

Core Viewpoint - Zhejiang Haisheng Medical Devices Co., Ltd. has passed the IPO review by the Beijing Stock Exchange, marking it as the 71st company to receive approval this year, with a total of 28 companies approved by the Beijing Stock Exchange [1] Company Overview - Haisheng Medical is a global provider of anesthesia and monitoring medical devices, focusing on the research, production, and sales of these products, which are widely used in various clinical departments such as anesthesia, ICU, and emergency [2] - The controlling shareholders of Haisheng Medical are Huang Haisheng and Wu Xiaoye, who together control 54.92% of the company's shares [2] IPO Details - Haisheng Medical plans to publicly issue up to 11,294,118 shares, or up to 12,988,235 shares if the overallotment option is fully exercised, ensuring that public shareholders hold at least 25% of the total share capital post-issue [3] - The company aims to raise approximately 370.43 million yuan, which will be allocated to upgrading and expanding production of anesthesia and monitoring emergency medical devices, establishing a research and testing center, and building a marketing service base [3] Review Meeting Inquiries - The review meeting raised inquiries regarding the authenticity and accuracy of financial information, the impact of industry policies such as volume-based procurement and the "two-invoice system" on the company's operational stability, and the progress of research and development for active devices [4]

Core Insights - Five companies are set to present their IPO applications, with the highest fundraising target being 1.555 billion yuan by Shaanxi Tourism [1] - The companies are distributed across different stock exchanges, including the Shanghai Stock Exchange, Shenzhen Stock Exchange, and Beijing Stock Exchange [1] Group 1: Companies and Their IPO Plans - Shaanxi Tourism aims to raise 1.555 billion yuan for various tourism-related projects, including acquisitions and infrastructure development [1][2] - Qiangyi Co., specializing in MEMS probe card manufacturing, plans to raise 1.5 billion yuan [1][3] - Haiseng Medical, focusing on anesthesia and monitoring medical devices, intends to raise 370 million yuan [1][4] - Guoliang New Materials, providing high-temperature industrial refractory solutions, is seeking to raise 175 million yuan [1][4] - Tongbao Optoelectronics, engaged in the design and production of automotive LED modules, plans to raise 330 million yuan [1][5] Group 2: Regional Distribution - Among the five companies, two are from Jiangsu Province, while one each is from Shaanxi, Zhejiang, and Hebei [1]

Core Viewpoint - Zhejiang Haisheng Medical Devices Co., Ltd. is entering the critical IPO review stage with the Beijing Stock Exchange, focusing on the development, production, and sales of anesthesia and monitoring medical devices [1][3] Group 1: Company Overview - The company has established a product matrix covering three main categories: anesthesia, monitoring, and surgical care, with eight major series including airway and respiratory management, life information monitoring, and spinal and nerve block [1] - Its products are widely used in over a thousand tertiary hospitals and thousands of medical institutions across China, including more than 600 top-tier hospitals such as Peking Union Medical College Hospital and Ruijin Hospital affiliated with Shanghai Jiao Tong University [1] Group 2: Financial and Operational Insights - In response to regulatory inquiries regarding the reasonableness of sales expense ratios, the company clarified that sales expenses are primarily allocated to academic promotion, dealer training, and market channel maintenance, aligning with industry peers like Weili Medical and Sanxin Medical [3] - The company plans to issue up to 11,294,118 shares to unspecified qualified investors, or up to 12,988,235 shares if the overallotment option is fully exercised, ensuring that public shareholders will hold at least 25% of the total share capital post-issuance [3] Group 3: Future Prospects - The raised funds will be used for upgrading and expanding production of emergency medical devices, establishing a research and testing center, and building a marketing service base [3] - With its core products already covering numerous key medical institutions and aligning with industry development trends, the company is expected to enhance its production capacity and technological transformation capabilities, thereby solidifying its competitive advantage in the anesthesia and monitoring medical device sector [3]

Core Insights - Five companies are set to present their IPO applications, with a focus on various sectors including tourism, medical devices, and advanced manufacturing [1] Group 1: Upcoming IPOs - Xi'an Tourism plans to raise 1.555 billion yuan, targeting multiple projects including the Taishan Xiucheng Phase II and acquisitions related to tourism infrastructure [1] - Qiangyi Co. aims to raise 1.5 billion yuan, specializing in MEMS probe card manufacturing, a niche technology in the semiconductor industry [4] - Zhixin Co. intends to raise 1.329 billion yuan, focusing on automotive welding components and related mold development [2] - Haiseng Medical seeks to raise 370 million yuan, engaged in the R&D and production of anesthesia and monitoring medical devices [5] - Guoliang New Materials plans to raise 175 million yuan, providing high-temperature industrial refractory material solutions [5] Group 2: Company Profiles - Xi'an Tourism integrates tourism performances, cable cars, dining, and project investment and management [3] - Qiangyi Co. is one of the few domestic manufacturers with the capability to produce MEMS probe cards in bulk [4] - Zhixin Co. specializes in the development, processing, and sales of automotive welding parts and molds [2] - Haiseng Medical focuses on high-tech medical devices for anesthesia and monitoring, serving critical care departments [5] - Guoliang New Materials offers comprehensive solutions for high-temperature refractory materials [5]

Core Viewpoint - This week (November 3 to November 7), five companies are scheduled for IPO meetings, with a total fundraising target of approximately 38.71 billion yuan [1]. Group 1: Upcoming IPOs - Five companies are set to present their IPO applications: Shaanxi Tourism and Zhixin Co. for the Shanghai main board, and Guoliang New Materials, Haiseng Medical, and Qilong Ocean for the Beijing Stock Exchange [1][2][4]. - Shaanxi Tourism aims to raise the highest amount of 1.555 billion yuan, with funds allocated for multiple projects including the Taishan Xiucheng Phase II project and various acquisitions [1][3]. - Zhixin Co. plans to raise 1.329 billion yuan, while Qilong Ocean aims for 382 million yuan [1]. Group 2: Company Profiles - Shaanxi Tourism integrates tourism performances, cable cars, dining, and project investment and management [3]. - Zhixin Co. specializes in the development, processing, production, and sales of automotive welding parts and related molds [2]. - Haiseng Medical focuses on the research, production, and sales of anesthesia and monitoring medical devices, serving various clinical needs [4]. - Guoliang New Materials provides high-temperature industrial refractory material solutions [4]. - Qilong Ocean is involved in the research, production, and sales of marine drilling riser systems and underwater oil and gas equipment testing services [4].

Core Viewpoint - The upcoming IPO review period from November 3 to November 7 will feature five companies aiming to raise a total of 3.812 billion yuan [1]. IPO Companies Overview - Five companies are scheduled for IPO review: - Qilong Ocean (Shandong) aims to raise 381.889 million yuan, with a net profit of 50.67 million yuan [2][5]. - Zhixin Co., Ltd. plans to raise 1.329 billion yuan, reporting a net profit of 203.964 million yuan [2][10]. - Shaanxi Tourism intends to raise 1.555 billion yuan, with a net profit of 621.578 million yuan [2][15]. - Haiseng Medical (Zhejiang) seeks to raise 370.425 million yuan, with a net profit of 70.918 million yuan [2][20]. - Guoliang New Materials (Hebei) aims to raise 175.022 million yuan, reporting a net profit of 70.965 million yuan [2][25]. Fundraising Adjustments - Guoliang New Materials reduced its fundraising target from 301 million yuan to 175 million yuan, eliminating the R&D center project and adjusting working capital needs [3]. Financial Performance - Qilong Ocean reported total assets of 432.166 million yuan and a net profit of 49.075 million yuan for the first half of 2025 [7]. - Zhixin Co., Ltd. had total assets of 427.830 million yuan and a net profit of 9.448 million yuan for the first half of 2025 [12]. - Shaanxi Tourism's total assets reached 214.426 million yuan with a net profit of 24.707 million yuan for the first half of 2025 [17]. - Haiseng Medical reported total assets of 519.449 million yuan and a net profit of 35.494 million yuan for the first half of 2025 [23]. - Guoliang New Materials had total assets of 1.520 billion yuan and a net profit of 41.497 million yuan for the first half of 2025 [26]. Investment Projects - Qilong Ocean's main investment project is the high-performance large-diameter riser pipe production project, with a total investment of 381.889 million yuan [9]. - Zhixin Co., Ltd. plans to expand its production capacity and technology for automotive welding components, with a total investment of 1.329 billion yuan [13]. - Shaanxi Tourism's investment projects include the construction of various tourism facilities, totaling 1.555 billion yuan [19]. - Haiseng Medical's investment projects focus on upgrading and expanding production capabilities for anesthesia and monitoring medical devices, with a total investment of 482.701 million yuan [24]. - Guoliang New Materials is involved in high-temperature industrial refractory materials, with a total investment of 175.022 million yuan for its projects [27].

Group 1 - The core point of the news is that Weili Medical's stock price increased by 5.13% to 14.76 CNY per share, with a trading volume of 102 million CNY and a turnover rate of 2.44%, resulting in a total market capitalization of 4.308 billion CNY [1] - Weili Medical, established on April 30, 2004, and listed on March 2, 2015, specializes in the research, production, and sales of medical devices in various fields including anesthesia, urology, catheterization, nursing, respiratory care, and dialysis [1] - The revenue composition of Weili Medical is as follows: anesthesia 31.62%, catheterization 29.03%, urology 14.32%, nursing 11.45%, respiratory care 5.56%, dialysis 5.01%, and others 3.01% [1] Group 2 - From the perspective of Weili Medical's top ten circulating shareholders, a fund under China Merchants Fund, specifically the China Merchants Quantitative Selected Stock Initiation A (001917), entered the top ten circulating shareholders in the third quarter, holding 1.8866 million shares, which accounts for 0.65% of the circulating shares [2] - The estimated floating profit for this fund today is approximately 1.3584 million CNY [2] - The China Merchants Quantitative Selected Stock Initiation A (001917) was established on March 15, 2016, with a latest scale of 2.765 billion CNY, achieving a year-to-date return of 40.44% and a one-year return of 47.04% [2]

Core Viewpoint - The company, Opcon Vision, has received a new medical device production license from the Anhui Provincial Drug Administration, indicating an expansion in its production capabilities and product range [2]. Group 1: License Update - The company has completed the change registration for its medical device production license [2]. - The new license includes an additional production address located at "No. 1, 1st Floor, Building C, 4899 Wangjiang West Road, High-tech Zone, Hefei" [2]. - The production scope has been expanded to include "08-05 respiratory, anesthesia, and emergency device auxiliary equipment" [2].

Core Points - Vili Medical's stock increased by 5.04% to 14.17 CNY per share, with a trading volume of 51.81 million CNY and a turnover rate of 1.27%, resulting in a total market capitalization of 4.15 billion CNY [1] - The company, established on April 30, 2004, and listed on March 2, 2015, specializes in the research, production, and sales of medical devices in various fields including anesthesia, urology, catheterization, nursing, respiratory care, and dialysis [1] - The revenue composition of Vili Medical is as follows: anesthesia 31.62%, catheterization 29.03%, urology 14.32%, nursing 11.45%, respiratory care 5.56%, dialysis 5.01%, and others 3.01% [1] Fund Holdings - The Xinda Australia Fund has a significant holding in Vili Medical, with the Xinda Small and Medium Cap Mixed A Fund (610004) reducing its stake by 69.96 thousand shares in the second quarter, now holding 77.05 thousand shares, which represents 4.54% of the fund's net value [2] - The fund has achieved a floating profit of approximately 523.9 thousand CNY as of the latest report [2] - The Xinda Small and Medium Cap Mixed A Fund was established on December 1, 2009, with a current size of 216 million CNY, and has recorded a year-to-date return of 24.01% [2] Fund Management - The fund is managed by Zeng Guofu and Li Diandian, with Zeng having a tenure of 17 years and 88 days, overseeing assets totaling 481 million CNY, achieving a best return of 109.1% during his tenure [3] - Li Diandian has been managing the fund for 1 year and 7 days, with assets of 570 million CNY, and has achieved a best return of 35.83% during his management period [3]